1
|
Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Őrfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Őrfi L, Vántus T, Kéri G. Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. ACS Med Chem Lett 2014; 5:298-303. [PMID: 24900830 DOI: 10.1021/ml4003309] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2013] [Accepted: 01/30/2014] [Indexed: 01/23/2023] Open
Abstract
Activating mutations in the epidermal growth factor receptor (EGFR) have been identified in a subset of non-small cell lung cancer (NSCLC), which is one of the leading cancer types worldwide. Application of EGFR tyrosine kinase inhibitors leads to acquired resistance by secondary EGFR mutations or by amplification of the hepatocyte growth factor receptor (c-Met) gene. Although several EGFR and c-Met inhibitors have been reported, potent dual EGFR/c-Met inhibitors, which can overcome this latter resistance mechanism, have hitherto not been published and have not reached clinical trials. In the present study we have identified dual EGFR/c-Met inhibitors and designed novel N-[4-(quinolin-4-yloxy)-phenyl]-biarylsulfonamide derivatives, which inhibit the c-Met receptor and both the wild-type and the activating mutant EGFR kinases in nanomolar range. We have demonstrated by Western blot analysis that compound 10 inhibits EGFR and c-Met phosphorylation at cellular level and effectively inhibits viability of the NSCLC cell lines.
Collapse
Affiliation(s)
| | - Pál Gyulavári
- MTA-SE
Pathobiochemistry Research Group, Department of Medical Chemistry, Semmelweis University, 1085 Budapest, Hungary
| | - Ibolya Kurkó
- Vichem Chemie Research Ltd., 1022 Budapest, Hungary
| | - Ferenc Baska
- Vichem Chemie Research Ltd., 1022 Budapest, Hungary
- Rational
Drug-Design Laboratory Cooperation Research Centre, Semmelweis University, 1085 Budapest, Hungary
| | | | - Zoltán Greff
- Vichem Chemie Research Ltd., 1022 Budapest, Hungary
| | - Zoltán Őrfi
- Rational
Drug-Design Laboratory Cooperation Research Centre, Semmelweis University, 1085 Budapest, Hungary
- Max Planck Institute of Biochemistry, Munich 82152, Germany
| | - István Peták
- MTA-SE
Pathobiochemistry Research Group, Department of Medical Chemistry, Semmelweis University, 1085 Budapest, Hungary
- KPS Medical Biotechnology and Healthcare Services Ltd., 1022 Budapest, Hungary
| | - Kinga Pénzes
- Max Planck Institute of Biochemistry, Munich 82152, Germany
| | - Robert Torka
- Max Planck Institute of Biochemistry, Munich 82152, Germany
| | - Axel Ullrich
- Max Planck Institute of Biochemistry, Munich 82152, Germany
| | - László Őrfi
- Vichem Chemie Research Ltd., 1022 Budapest, Hungary
- Department
of Pharmaceutical Chemistry, Semmelweis University, 1085 Budapest, Hungary
| | - Tibor Vántus
- MTA-SE
Pathobiochemistry Research Group, Department of Medical Chemistry, Semmelweis University, 1085 Budapest, Hungary
| | - György Kéri
- Vichem Chemie Research Ltd., 1022 Budapest, Hungary
- MTA-SE
Pathobiochemistry Research Group, Department of Medical Chemistry, Semmelweis University, 1085 Budapest, Hungary
- Rational
Drug-Design Laboratory Cooperation Research Centre, Semmelweis University, 1085 Budapest, Hungary
| |
Collapse
|